In the supernatants of US-treated cancer cells, we also detected upregulated levels of uPA and VEGF-A, the first of which has been reported to be positively associated with increased PC severity and poor clinical outcome [65], while the latter is generally found to be significantly elevated in cancer patients, including those with PC, compared to the results for healthy individuals [66]. The gene discussed is VEGFA; the disease is pachyonychia congenita.